207 related articles for article (PubMed ID: 35017155)
1. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
Bertucci F; Niziers V; de Nonneville A; Finetti P; Mescam L; Mir O; Italiano A; Le Cesne A; Blay JY; Ceccarelli M; Bedognetti D; Birnbaum D; Mamessier E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017155
[TBL] [Abstract][Full Text] [Related]
2. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
Bertucci F; De Nonneville A; Finetti P; Perrot D; Nilbert M; Italiano A; Le Cesne A; Skubitz KM; Blay JY; Birnbaum D
Ann Oncol; 2018 Feb; 29(2):459-465. PubMed ID: 29069276
[TBL] [Abstract][Full Text] [Related]
3. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A; Finetti P; Denicolai E; Greillier L; Boudou-Rouquette P; Goldwasser F; Lumet G; Ceccarelli M; Birnbaum D; Bedognetti D; Mamessier E; Barlesi F; Bertucci F; Tomasini P
J Transl Med; 2023 Sep; 21(1):637. PubMed ID: 37726776
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
[TBL] [Abstract][Full Text] [Related]
5. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
Bertucci F; Finetti P; Simeone I; Hendrickx W; Wang E; Marincola FM; Viens P; Mamessier E; Ceccarelli M; Birnbaum D; Bedognetti D
Br J Cancer; 2018 Nov; 119(11):1383-1391. PubMed ID: 30353048
[TBL] [Abstract][Full Text] [Related]
6. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
[TBL] [Abstract][Full Text] [Related]
7. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
8. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.
Lesluyes T; Pérot G; Largeau MR; Brulard C; Lagarde P; Dapremont V; Lucchesi C; Neuville A; Terrier P; Vince-Ranchère D; Mendez-Lago M; Gut M; Gut I; Coindre JM; Chibon F
Eur J Cancer; 2016 Apr; 57():104-11. PubMed ID: 26916546
[TBL] [Abstract][Full Text] [Related]
9. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
10. CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond.
Chibon F; Lesluyes T; Valentin T; Le Guellec S
Genes Chromosomes Cancer; 2019 Feb; 58(2):124-129. PubMed ID: 30387235
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
Shen R; Liu B; Li X; Yu T; Xu K; Ma J
BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
[TBL] [Abstract][Full Text] [Related]
12. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
13. Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03).
Jakob J; Lesluyes T; Simeonova-Chergou A; Wenz F; Hohenberger P; Chibon F; Le Guellec S
Strahlenther Onkol; 2020 Mar; 196(3):280-285. PubMed ID: 31732782
[TBL] [Abstract][Full Text] [Related]
14. A Global and Integrated Analysis of CINSARC-Associated Genetic Defects.
Lesluyes T; Chibon F
Cancer Res; 2020 Dec; 80(23):5282-5290. PubMed ID: 33023949
[TBL] [Abstract][Full Text] [Related]
15. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms.
Lesluyes T; Delespaul L; Coindre JM; Chibon F
Sci Rep; 2017 Jul; 7(1):5480. PubMed ID: 28710396
[TBL] [Abstract][Full Text] [Related]
16. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
Frezza AM; Stacchiotti S; Chibon F; Coindre JM; Italiano A; Romagnosa C; Bagué S; Dei Tos AP; Braglia L; Palmerini E; Quagliuolo V; Broto JM; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Beveridge RD; Lugowska I; Lesluyes T; Maestro R; Merlo FD; Casali PG; Gronchi A
Cancer Med; 2023 Jan; 12(2):1350-1357. PubMed ID: 35848358
[TBL] [Abstract][Full Text] [Related]
17. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
Chibon F; Lagarde P; Salas S; Pérot G; Brouste V; Tirode F; Lucchesi C; de Reynies A; Kauffmann A; Bui B; Terrier P; Bonvalot S; Le Cesne A; Vince-Ranchère D; Blay JY; Collin F; Guillou L; Leroux A; Coindre JM; Aurias A
Nat Med; 2010 Jul; 16(7):781-7. PubMed ID: 20581836
[TBL] [Abstract][Full Text] [Related]
18. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
19. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
[TBL] [Abstract][Full Text] [Related]
20. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
